Last 26 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.03 | 3.83 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.44 | 0.26 | — | 4.18 | — | — | — | — | 1.93 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | — | — | — | — | — | — | 36.93 | 2.07 | 3.70 | 2.11 | 3.33 | 1.67 | 0.86 | 1.15 | 0.82 | 2.01 | 2.03 | 0.65 | 0.98 | 3.14 | 4.33 |
| — | — | — | — | — | — | +1009.9% | +23.8% | +331.4% | +83.2% | +308.2% | -16.9% | -57.6% | +77.8% | -17.0% | -35.8% | -53.2% | -91.9% | -88.7% | -42.5% | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 155.53 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 155.53 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -2053.7% | 100.0% | — | 140.3% | — | — | — | — | 97.9% | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -2965.3% | 3.5% | — | -462.8% | — | — | — | — | -102.5% | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -2980.3% | 7.0% | — | -489.2% | — | — | — | — | -96.2% | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | -207.0% | -80.0% | -39.0% | -52.0% | -38.6% | -32.6% | -30.4% | -25.5% | -16.3% | -17.1% | -16.8% | -16.3% | -12.1% | -10.6% | -11.2% |
| — | — | — | — | — | — | -436.4% | -145.5% | -28.2% | -104.2% | -136.7% | -90.9% | -81.4% | -56.3% | -34.8% | -61.0% | -49.4% | -0.2% | -31.3% | +56.2% | — | |
| ROA | -179.9% | 5.0% | -56.7% | -65.8% | -73.3% | -57.2% | -33.8% | -26.0% | -16.2% | -26.7% | -22.2% | -19.9% | -20.1% | -18.6% | -12.8% | -13.3% | -12.8% | -13.0% | -10.0% | -8.8% | -9.3% |
| — | +108.7% | -67.6% | -153.5% | -353.2% | -114.2% | -52.0% | -30.7% | +19.7% | -43.5% | -74.3% | -49.6% | -57.2% | -43.0% | -27.6% | -51.0% | -38.0% | +4.5% | -26.7% | +17.5% | +49.9% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 1.01 | 0.06 | 0.05 | 0.05 | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | — |
| — | — | — | — | — | — | +2517.0% | +68.4% | +81.2% | +104.2% | +67.8% | +57.7% | -1.3% | -9.1% | -13.0% | -13.4% | — | +644.7% | +661.8% | +684.4% | — | |
| Debt / EBITDA | — | 325.72 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.37 | 0.20 | 0.15 | 0.37 | 0.54 | 1.24 | 2.35 | 3.52 | 3.11 | 3.81 | 4.49 | 4.11 | 4.14 | 5.21 | 7.61 | 9.53 | 7.69 | 8.12 | 13.03 | 12.48 | 6.05 |
| — | -83.7% | -93.6% | -89.6% | -82.7% | -67.4% | -47.7% | -14.2% | -24.9% | -26.9% | -41.0% | -56.9% | -46.1% | -35.9% | -41.6% | -23.6% | +27.2% | +38.3% | +77.2% | +67.3% | +275.9% | |
| Quick Ratio | 0.37 | 0.20 | 0.15 | 0.37 | 0.54 | 1.24 | 2.35 | 3.52 | 3.11 | 3.81 | 4.49 | 4.11 | 4.14 | 5.21 | 7.61 | 9.53 | 7.69 | 8.12 | 13.03 | 12.48 | 6.05 |
| — | -83.7% | -93.6% | -89.6% | -82.7% | -67.4% | -47.7% | -14.2% | -24.9% | -26.9% | -41.0% | -56.9% | -46.1% | -35.9% | -41.6% | -23.6% | +27.2% | +38.3% | +77.2% | +67.3% | +275.9% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 26 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BCAB stock.
BioAtla, Inc.'s current P/E is -0.0x. The average P/E over the last 1 quarters is 3.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
BioAtla, Inc.'s current operating margin is -2965.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BioAtla, Inc.'s business trajectory between earnings reports.